Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Comment by IrishCanuckon Nov 26, 2020 3:46pm
166 Views
Post# 31982923

RE:Strategic Exit?

RE:Strategic Exit?Correct, you can buy Otena without buying the company and ATE loses all future rights to it, or we could sell it but retain royalties. There are a thousand business deals that could be structured. Pharma could buy ATE or just Otena and leave other IP intact. Both would make the share price go up

1) If we sold Otena then ATE gets cash and retains IP. That way the market value of each share is more subjective. If ATE received a billion dollars cash then maybe we'd get $800 million market cap because people would allocate $200 million off the top for further R&D, therefore its removed from shareholder value

2) If Pharma is buying the company at $4 per share for example, you're not going to see much buying and selling of shares other than around the $4 mark

I hope that helps
<< Previous
Bullboard Posts
Next >>